Campbell & CO Investment Adviser LLC Makes New $1.81 Million Investment in DexCom, Inc. $DXCM

Key Points

• Campbell & CO Investment Adviser LLC has made a new investment in DexCom, Inc., acquiring 26,506 shares valued at approximately $1.81 million.
• In recent months, several hedge funds, including Golden State Wealth Management LLC, have significantly increased their positions in DexCom, indicating growing institutional interest in the company.
• DexCom reported a quarterly earnings per share of $0.48, surpassing estimates and demonstrating a 15.2% increase in revenue year-over-year.

Campbell & CO Investment Adviser LLC acquired a new position in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 26,506 shares of the medical device company's stock, valued at approximately $1,810,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Golden State Wealth Management LLC raised its stake in shares of DexCom by 211.2% in the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company's stock worth $27,000 after buying an additional 264 shares in the last quarter. Zions Bancorporation National Association UT bought a new stake in shares of DexCom in the 1st quarter worth $27,000. Optiver Holding B.V. bought a new stake in shares of DexCom in the 4th quarter worth $33,000. Heck Capital Advisors LLC bought a new stake in shares of DexCom in the 4th quarter worth $38,000. Finally, Alpine Bank Wealth Management bought a new stake in shares of DexCom in the 1st quarter worth $40,000. Institutional investors own 97.75% of the company's stock.

DexCom Stock Up 0.3%

Shares of DXCM stock traded up $0.26 on Friday, reaching $75.34. 2,921,932 shares of the company's stock traded hands, compared to its average volume of 4,070,578. DexCom, Inc. has a 12-month low of $57.52 and a 12-month high of $93.25. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.35 and a current ratio of 1.52. The company has a market capitalization of $29.54 billion, a P/E ratio of 52.32, a price-to-earnings-growth ratio of 1.58 and a beta of 1.48. The business's 50 day moving average price is $82.25 and its two-hundred day moving average price is $79.41.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The medical device company reported $0.48 earnings per share for the quarter, beating analysts' consensus estimates of $0.45 by $0.03. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The business had revenue of $1.16 billion for the quarter, compared to the consensus estimate of $1.13 billion. During the same quarter in the previous year, the company posted $0.43 earnings per share. DexCom's revenue for the quarter was up 15.2% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. On average, equities analysts forecast that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Transactions at DexCom

In other DexCom news, EVP Michael Jon Brown sold 500 shares of the business's stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the transaction, the executive vice president owned 94,102 shares in the company, valued at $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Sadie Stern sold 1,466 shares of the business's stock in a transaction dated Monday, July 28th. The shares were sold at an average price of $88.99, for a total value of $130,459.34. Following the completion of the transaction, the executive vice president owned 106,689 shares in the company, valued at $9,494,254.11. This trade represents a 1.36% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,722 shares of company stock worth $1,306,131. 0.32% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

DXCM has been the topic of a number of recent research reports. Citigroup restated a "buy" rating and issued a $102.00 target price (up from $82.00) on shares of DexCom in a report on Thursday, May 22nd. Morgan Stanley lifted their target price on DexCom from $82.00 to $89.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. The Goldman Sachs Group initiated coverage on DexCom in a report on Friday, May 30th. They issued a "buy" rating and a $104.00 target price on the stock. Oppenheimer lifted their target price on DexCom from $95.00 to $102.00 and gave the stock an "outperform" rating in a report on Thursday, July 31st. Finally, Canaccord Genuity Group restated a "buy" rating and issued a $106.00 target price on shares of DexCom in a report on Friday, August 1st. Three research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $99.89.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.